|
|
News for Healthier Living
FDA Approves Immune Checkpoint Inhibitor Drug for Patients with Resectable Locally Advanced Head and Neck Cancer, Backed by Dana-Farber Research
 Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) greater than or equal to 1] as determined by an FDA-approved test.
June 13, 2025
June 14 2025June 13 2025June 12 2025June 11 2025June 10 2025June 9 2025June 8 2025June 7 2025June 6 2025June 5 2025June 4 2025June 3 2025June 2 2025June 1 2025
|
|
|
|
|